部份中文普鲁士兰处方资料（仅供参考）
商品名：Radiogardase Capsule
英文名：Prussian Blue
中文名：普鲁士兰胶囊
生产商：Nihon Medi-Physics
药品简介
Radiogardase（Prussian blue,ヘキサシアノ鉄(II)酸鉄(III)水和物 ）属于药物类解毒剂，临床用于放射急症的治疗（对已知或怀疑体内受到放射性铯和/或放射性或非放射性铊污染的患者，以提高其清除率）。
ラディオガルダーゼカプセル500mg
药用类别名称
解毒药
批准日期：2010年12月
商標名
RADIOGARDASE Capsules
一般的名称
ヘキサシアノ鉄（Ⅱ）酸鉄（Ⅲ）水和物
化学名
Iron(Ⅲ)hexacyanoferrate(Ⅱ)
分子式
Fe7C18N18・xH2O（x=14〜16）
分子量
859.23（脱水和物として）
性状
蓝紫色粒状结晶性粉末。
化学構造式
 注）x=14〜16
使用注意事项
外箱开封后应遮光保存。
药效药理
作用机制
放射性铯的排泄促进作用
对投用放射性铯（137Cs）的大鼠，在投用放射性铯后立即口服本制剂11天时，血液、肝脏、肾脏、脾脏、股骨及全身的放射能减少。
铊的排泄促进作用
对静脉注射放射性铊（204T1）的大鼠，在9天内混食本制剂时，放射性在累积粪便中的排泄量增加，体内滞留量降低。
适应症
○放射性铯对体内污染的减轻
○铊及铊化合物中毒
用法与用量
通常，1次口服6粒胶囊（作为己氰铁（Ⅱ）酸铁（Ⅲ）水合物3g），1天3次。另外，根据患者的状态、年龄、体重适当增减。
临床结果
有效性及安全性试验
放射性铯的排泄促进作用
对7例经口摄取放射性铯（137Cs:37kBq）的外国健康成人，每天3次给予1.0g本制剂时，放射性铯的生物半衰期平均值从94天缩短到31天。
放射性铯辐射事故
在巴西戈亚尼亚的事故中，对46例受到放射性铯（137Cs）体内污染的患者给予了本制剂。成人及年轻成人每天口服本制剂3～10g，儿童每天口服本制剂1～3g，或分6次（给药间隔根据给药量调整，以最短2小时间隔给药）。关于46例中的25例，得到了本制剂给药过程中以及停止给药后放射性铯的生物半衰期的数据（表1），通过本制剂给药，放射性铯的生物半衰期缩短。另外，通过使用本制剂，粪便中/尿中的放射性排泄比增加。
铊的排泄促进作用
对于2名铊中毒的外国患者，每天给予6g的本制剂，分别为5天或22天。在所有病例中，粪便中和尿中的铊排泄量增加，脱毛等症状得到改善。另外，对1名铊中毒患者，每天3次、2周给予1.5g本制剂。结果，血中铊浓度降低，感觉异常等症状得到改善。
包装
36胶囊[1]容器
制造和销售来源
日本MEJIFIJIX株式会社
Nippon Medical Physics Co.Ltd. 
提携先
HEYL Chemisch-pharmazeutische Fabrik GmbH ＆Co.KG
Berlin Germany
参考信息
打开容器：
本制剂容器的盖子采用了儿童锁，请按照以下步骤开封。
注：以上中文处方资料不够完整，使用者以原处方资料为准。
完整资料附件：
https://www.info.pmda.go.jp/go/pack/392900XM1028_1_
06/392900XM1028_1_06?view=body&lang=ja
-----------------------------------------------------------
Notice of acquisition of radioactive cesium removal Agent "Lasdigalidase® Capsules 500mg" approved
-The first domestic introduction of international standard drugs to reduce the internal contamination and efficacy Japan Medi-Physics Co., Ltd. (Head Office: Tokyo Koto-ku, President: Makoto Mikami) is a medicament to reduce the body contamination by radioactive cesium (137Cs, etc.) to the efficacy and effect of the drug "Lasdigalidase® Capsule 500mg" (hereinafter, "
We have obtained the approval of production and sales on October 27.
This agent is a developer and will be released as soon as the sales system is ready by our company to import and sell this agent in Japan by partnering with Hyle (Heyl), a Germany with a proven manufacturing supply in other countries. Radioactive cesium is included in waste materials in nuclear facilities, and there is a risk of radiation exposure in the event of a disaster. It is also one of the radioactive isotopes used extensively in medical (radioactive radiation sources for cancer treatment) and industrial (sterilization and measurement).
In order to reduce internal contamination in the event of radioactive cesium exposure, it is desirable to administer this agent orally within as short a period of time as possible, and it is expected that the stockpile will be promoted in the emergency medical response institutions and disaster base hospitals in Japan. In addition to the Strategic National Stockpile system, the national stockpile has been started United States internationally, and the World Health Organization (WHO) Essential Medicine
　It is regarded as one of the standard radioactive cesium removal agents, such as being raised on the list of stockpile recommendations. On the other hand, in Japan, the Ministry of Health, Labour and Welfare has received a request for introduction from the relevant academic societies at the Conference on the examination of an unapproved drug and an adaptive medicine that requires medical care. It is hoped that the institutional framework to promote the proper stockpiling system will be newly developed from the standpoint of nuclear disaster countermeasures or the National Protection plan.
Our company recognizes the social needs of this agent, and wants to contribute to the nuclear disaster countermeasures in Japan through the supply of this agent. Japan Medi-Physics Co., Ltd. has been engaged in the development, manufacture and supply of high-quality radioactive medicines used in the diagnosis of nuclear medicine, which is useful for early diagnosis of disease. We will continue to contribute to the further development of medical care in Japan those targets. Japan Medi-Physics Co., Ltd. is a joint venture of Sumitomo Chemical Corporation and GE Healthcare (United Kingdom), a leading manufacturer of radioactive pharmaceuticals.
Overview of radioactive cesium Body Removal Agent "Lasdigalidase® Capsules 500mg"　　
Product Name: Japanese name Lasdigalidase® Capsules 500mg
Western Name RADIOGARDASE®
General Name: Japanese name Hexacyano iron (II) acid iron (III) hydrate
Efficacy or efficacy: reduction of internal contamination by radioactive cesium Dosage: Usually, once 6 capsules (3g as Hexaniiron (II) iron (III) hydrate) is administered orally three times a day. In addition, the patient's condition, age, and increase or decrease depending on the weight.